Cargando…

Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom

BACKGROUND: The use of zoledronic acid (ZOL) has recently been shown to significantly reduce the risk of new skeletal-related events (SREs) in renal cell carcinoma (RCC) patients with bone metastases. The present exploratory study assessed the cost-effectiveness of ZOL in this population, adopting a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botteman, M. F., Meijboom, M., Foley, I., Stephens, J. M., Chen, Y. M., Kaura, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197935/ https://www.ncbi.nlm.nih.gov/pubmed/20809091 http://dx.doi.org/10.1007/s10198-010-0272-0

Ejemplares similares

Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Hechmati, Guy, et al.
Publicado: (2014)

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Qian, Yi, et al.
Publicado: (2018)

The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom
por: McCrone, Paul, et al.
Publicado: (2011)

The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study
por: Goring, S. M., et al.
Publicado: (2018)

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017)

International Pharmaceutical Spending Controls: France, Germany, Sweden, and the United Kingdom
por: Gross, David J., et al.
Publicado: (1994)

Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2013)

Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland
por: Lothgren, Mickael, et al.
Publicado: (2013)

Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada
por: Smith-Palmer, J., et al.
Publicado: (2019)

Health state utilities for skeletal-related events secondary to bone metastases
por: Matza, Louis S., et al.
Publicado: (2013)

A Modified Method for Reducing Renal Injury in Zoledronic Acid Treatment of Hypercalcemia and Adverse Skeletal Events
por: Liu, Jiang, et al.
Publicado: (2013)

Institutional environments and breakthroughs in science. Comparison of France, Germany, the United Kingdom, and the United States
por: Heinze, Thomas, et al.
Publicado: (2020)

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
por: Durán, I., et al.
Publicado: (2013)

Emotional reactions to climate change: a comparison across France, Germany, Norway, and the United Kingdom
por: Böhm, Gisela, et al.
Publicado: (2023)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Predicting EQ-5D-5L crosswalk from the PROMIS-29 profile for the United Kingdom, France, and Germany
por: Klapproth, Christoph Paul, et al.
Publicado: (2020)

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
por: de la Piedra, C, et al.
Publicado: (2013)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
por: Mytelka, Daniel S., et al.
Publicado: (2018)

COVID-19 and Territorial Policy Dynamics in Western Europe: Comparing France, Spain, Italy, Germany, and the United Kingdom
por: Vampa, Davide
Publicado: (2021)

Potato Production in Northwestern Europe (Germany, France, the Netherlands, United Kingdom, Belgium): Characteristics, Issues, Challenges and Opportunities
por: Goffart, Jean-Pierre, et al.
Publicado: (2022)

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
por: Steinman, Richard A, et al.
Publicado: (2012)

Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom
por: Mohty, Mohamad, et al.
Publicado: (2020)

Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
por: Knight, Tyler, et al.
Publicado: (2013)

The Baths of Germany, France, and Switzerland
Publicado: (1857)

The Asylums of Italy, France, and Germany
por: Arlidge, J. T.
Publicado: (1859)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

The "Partage ta science" event for secondary schools in France and Switzerland
por: Ordan, Julien
Publicado: (2023)

Predicting the number of reported and unreported cases for the COVID-19 epidemics in China, South Korea, Italy, France, Germany and United Kingdom
por: Liu, Z., et al.
Publicado: (2021)

Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany
por: He, Jianming, et al.
Publicado: (2021)

Bone metastases and skeletal-related events from neuroendocrine tumors
por: Van Loon, Katherine, et al.
Publicado: (2015)

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy
por: Pöhlmann, J., et al.
Publicado: (2020)

The Asylums of Italy, Germany, and France, &c.
por: Arlidge, J. T.
Publicado: (1858)

Notes on the Asylums of Italy, France, and Germany
por: Arlidge, J. T.
Publicado: (1860)

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017)

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
por: Dranitsaris, George, et al.
Publicado: (2012)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
por: Stephens, Stephanie, et al.
Publicado: (2015)

Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
por: Darbà, Josep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r01hlggpdl8hj8no759mhrth6s